Revance Therapeutics, Inc. Annual Depreciation, Depletion and Amortization in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
Revance Therapeutics, Inc. quarterly/annual Depreciation, Depletion and Amortization history and growth rate from 2019 to 2023.
  • Revance Therapeutics, Inc. Depreciation, Depletion and Amortization for the quarter ending March 31, 2024 was $1.98M, a 53.9% decline year-over-year.
  • Revance Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2023 was $11.4M, a 66.3% decline from 2022.
  • Revance Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2022 was $33.7M, a 69.9% increase from 2021.
  • Revance Therapeutics, Inc. annual Depreciation, Depletion and Amortization for 2021 was $19.9M, a 93.7% increase from 2020.
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $11.4M -$22.4M -66.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $33.7M +$13.9M +69.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $19.9M +$9.6M +93.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $10.3M +$7.34M +252% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $2.91M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.